keyword
https://read.qxmd.com/read/37986908/identification-of-nanoluciferase-substrates-transported-by-human-abcb1-and-abcg2-and-their-zebrafish-homologs-at-the-blood-brain-barrier
#21
Collin T Inglut, John A Quinlan, Robert W Robey, Joanna R Thomas, Joel R Walker, Wenhui Zhou, Huang-Chiao Huang, Michael M Gottesman
UNLABELLED: ATP-binding cassette (ABC) transporters expressed at the blood-brain barrier (BBB) impede delivery of therapeutic agents to the brain, including agents to treat neurodegenerative diseases and primary and metastatic brain cancers. Two transporters, P-glycoprotein (P-gp, ABCB1) and ABCG2, are highly expressed at the BBB and are responsible for the efflux of numerous clinically useful chemotherapeutic agents, including irinotecan, paclitaxel, and doxorubicin. Based on a previous mouse model, we have generated transgenic zebrafish in which expression of NanoLuciferase (NanoLuc) is controlled by the promoter of glial fibrillary acidic protein, leading to expression in zebrafish glia...
October 23, 2023: bioRxiv
https://read.qxmd.com/read/37841639/non-steroidal-fxr-agonist-cilofexor-improves-cholestatic-liver-injury-in-the-mdr2-mouse-model-of-sclerosing-cholangitis
#22
JOURNAL ARTICLE
Claudia D Fuchs, Natalie Sroda, Hubert Scharnagl, Ruchi Gupta, Wesley Minto, Tatjana Stojakovic, John T Liles, Grant Budas, David Hollenback, Michael Trauner
BACKGROUND & AIMS: The nuclear receptor farnesoid X receptor (FXR) is a key regulator of hepatic bile acid (BA) and lipid metabolism, inflammation and fibrosis. Here, we aimed to explore the potential of cilofexor (GS-9674), a non-steroidal FXR agonist, as a therapeutic approach for counteracting features of cholestatic liver injury by evaluating its efficacy and mechanisms in the Mdr2/Abcb4 knockout (-/- ) mouse model of sclerosing cholangitis. METHODS: FVB/N wild-type and Mdr2 -/- or BALB/c wild-type and Mdr2 -/- mice were treated with 0, 10, 30 or 90 mg/kg cilofexor by gavage every 24 h for 10 weeks...
November 2023: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/37822304/recurrent-early-onset-severe-obstetric-cholestasis-in-a-patient-with-two-variants-in-the-abcb4-gene
#23
Mohammad Fawad Khattak, Sam Thomson
A 36-year-old patient presented with severe early-onset obstetric cholestasis on a background of having pre-term induction of labor at 33 weeks during her only previous pregnancy. The patient had significantly abnormal liver biochemistry with a bilirubin of 78 µmol/L, ALP of 318 u/L, ALT of 280 µmol/L, and bile acid levels of 420 µmol/L. The patient received ursodeoxycholic acid 750 mg 3 times a day, rifampicin 500 mg twice a day, aspirin 150 mg once a day, and metformin 500 mg 3 times a day...
2023: Hepatol Forum
https://read.qxmd.com/read/37818704/obeticholic-acid-as-a-second-line-treatment-for-low-phospholipid-associated-cholelithiasis-syndrome
#24
JOURNAL ARTICLE
Pierre-Antoine Soret, Sara Lemoinne, Maxime Mallet, Karima Ben Belkacem, Olivier Chazouillères, Christophe Corpechot
BACKGROUND: Low phospholipid-associated cholelithiasis (LPAC) syndrome is a rare genetic cause of hepatolithiasis. A pathogenic variant of the ABCB4 gene is reported in half of all patients. Ursodeoxycholic acid (UDCA) is the only drug approved. However, in some patients, UDCA fails to prevent recurrence of symptoms and complications. Experimental evidence suggests that agonists of the farnesoid-X receptor (FXR), the main transcription factor regulating ABCB4, may be beneficial in this context...
January 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/37787087/a-novel-heterozygous-deletion-in-abcb4-gene-in-a-chinese-family-with-intrahepatic-cholestasis-of-pregnancy-neonatal-hyperbilirubinemia-and-cholelithiasis-case-reports-and-literature-review
#25
REVIEW
Yang Zheng, Qunfang Rao, Yiru Han, Jianqin He
BACKGROUND: ABCB4 gene (OMIM *171060) variant is associated with a wide clinical spectrum of hepatobiliary diseases, including familial intrahepatic cholestasis of pregnancy (ICP), progressive familial intrahepatic cholestasis type 3 (PFIC3), and neonatal hyperbilirubinemia due to impaired protection of the bile duct. The majority of reported cases, however, were missense or nonsense variants, with few deletion variant findings in the Chinese population. METHOD: We performed whole genome sequencing and confirmed it with Sanger sequencing of the proband infant and his families...
January 2024: Molecular Genetics & Genomic Medicine
https://read.qxmd.com/read/37701337/outcomes-of-38-patients-with-pfic3-impact-of-genotype-and-of-response-to-ursodeoxycholic-acid-therapy
#26
JOURNAL ARTICLE
Emmanuel Gonzales, Antoine Gardin, Marion Almes, Amaria Darmellah-Remil, Hanh Seguin, Charlotte Mussini, Stéphanie Franchi-Abella, Mathieu Duché, Oanez Ackermann, Alice Thébaut, Dalila Habes, Bogdan Hermeziu, Martine Lapalus, Thomas Falguières, Jean-Philippe Combal, Bernard Benichou, Sonia Valero, Anne Davit-Spraul, Emmanuel Jacquemin
BACKGROUND & AIMS: Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare liver disease caused by biallelic variations in ABCB4 . Data reporting on the impact of genotype and of response to ursodeoxycholic acid (UDCA) therapy on long-term outcomes are scarce. METHODS: We retrospectively describe a cohort of 38 patients with PFIC3 with a median age at last follow-up of 19.5 years (range 3.8-53.8). RESULTS: Twenty patients presented with symptoms before 1 year of age...
October 2023: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/37697751/the-mutational-landscape-of-genetic-cholestatic-diseases-in-pakistani-children
#27
JOURNAL ARTICLE
Huma Arshad Cheema, Nadia Waheed, Anjum Saeed, Muhammad Nadeem Anjum, Zafar Fayyaz, Sadaqat Ijaz
OBJECTIVES: To report the mutational landscape of a clinically diagnosed cohort of paediatric patients with cholestasis liver diseases. METHODS: The retrospective study was conducted at the University of Child Health Sciences, The Children Hospital, Lahore, Pakistan, from December 10, 2021, to March 31, 2022, and comprised data collected from the Paediatric Gastroenterology and Hepatology unit on demographics, clinical and laboratory findings related to children of either gender aged <12 years and diagnosed with cholestatic liver disease from July 2018 to June 2021...
August 2023: JPMA. the Journal of the Pakistan Medical Association
https://read.qxmd.com/read/37674192/generation-and-characterization-of-a-zebrafish-knockout-model-of%C3%A2-abcb4-a-homolog-of-the-human-multidrug-efflux-transporter-p-glycoprotein
#28
JOURNAL ARTICLE
Jinhee Park, Hyosung Kim, Leen Alabdalla, Smriti Mishra, Hassane Mchaourab
The ATP-binding cassette subfamily B member 1 (ABCB1), encoding a multidrug transporter referred to as P-glycoprotein (Pgp), plays a critical role in the efflux of xenobiotics in humans and is implicated in cancer resistance to chemotherapy. Therefore, developing high-throughput animal models to screen for Pgp function and bioavailability of substrates and inhibitors is paramount. Here, we generated and validated a zebrafish knockout line of abcb4, a human Pgp transporter homolog. CRISPR/Cas9 genome editing technology was deployed to generate a frameshift mutation in exon 4 of zebrafish abcb4...
September 6, 2023: Human Genomics
https://read.qxmd.com/read/37584002/-abcb4-gene-mutation-associated-cirrhosis-with-systemic-amyloidosis-a-case-report
#29
Na Cheng, Yu-Jie Qin, Quan Zhang, Hong Li
BACKGROUND: Gene mutations in ATP-binding cassette, subfamily B ( ABCB4 ) lead to autosomal recessive disorders. Primary light amyloidosis is a rare and incurable disease. Here, we report a rare case of liver cirrhosis caused by ABCB4 gene mutation combined with primary light amyloidosis. CASE SUMMARY: We report a case of a 25-year-old female who was hospitalized due to recurrent abdominal pain caused by calculous cholecystitis and underwent cholecystectomy. Pathological examination of the liver tissue suggested liver cirrhosis with bile duct injury...
July 16, 2023: World Journal of Clinical Cases
https://read.qxmd.com/read/37575491/variable-intrafamilial-expression-of-abcb4-disease
#30
Lucia Zampaglione, Anne-Laure Rougemont, Laura Rubbia-Brandt, Marc Abramowicz, Michel Guipponi, Enrica Marchionni, McLin Valerie, Nicolas Goossens
Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare cholestatic liver disease with autosomal recessive inheritance caused by mutations in the ABCB4 gene. The clinical presentation of PFIC3 varies significantly, displaying incomplete penetrance without clear genotype-phenotype correlations. As such, the suitability of living-related liver donation for children with advanced disease has been questioned. We report here the long-term follow-up of a patient with PFIC3 resulting in decompensated cirrhosis at 11 years who successfully underwent living donor liver transplantation from his father, who carried the same ABCB4 homozygous mutation...
August 2023: ACG Case Reports Journal
https://read.qxmd.com/read/37572734/glp-2-improves-hepatic-inflammation-and-fibrosis-in-mdr2-mice-via-activation-of-nr4a1-nur77-in-hepatic-stellate-cells-and-intestinal-fxr-signaling
#31
JOURNAL ARTICLE
Claudia D Fuchs, Thierry Claudel, Veronika Mlitz, Alessandra Riva, Moritz Menz, Ksenia Brusilovskaya, Felix Haller, Maximilian Baumgartner, Philipp Königshofer, Lukas W Unger, Wilhelm Sjöland, Hubert Scharnagl, Tatjana Stojakovic, Georg Busslinger, Thomas Reiberger, Hanns-Ulrich Marschall, Michael Trauner
BACKGROUND & AIMS: Glucagon-like peptide (GLP)-2 may exert antifibrotic effects on hepatic stellate cells (HSCs). Thus, we aimed to test whether application of the GLP-2 analogue teduglutide has hepatoprotective and antifibrotic effects in the Mdr2/Abcb4-/- mouse model of sclerosing cholangitis displaying hepatic inflammation and fibrosis. METHODS: Mdr2-/- mice were injected daily for 4 weeks with teduglutide followed by gene expression profiling (bulk liver; isolated HSCs) and immunohistochemistry...
August 10, 2023: Cellular and Molecular Gastroenterology and Hepatology
https://read.qxmd.com/read/37546821/generation-and-characterization-of-a-zebrafish-knockout-model-of%C3%A2-abcb4-a-homolog-of-the-human-multidrug-efflux-transporter-p-glycoprotein
#32
Jinhee Park, Hyosung Kim, Leen Alabdalla, Smriti Mishra, Hassane Mchaourab
The ATP-binding cassette subfamily B member 1 (ABCB1), encoding a multidrug transporter referred to as P-glycoprotein (Pgp), plays a critical role in the efflux of xenobiotics in humans and is implicated in cancer resistance to chemotherapy. Therefore, developing high throughput animal models to screen for Pgp function and bioavailability of substrates and inhibitors is paramount. Here, we generated and validated a zebrafish knockout line of abcb4 , a human Pgp transporter homolog. CRISPR/Cas9 genome editing technology was deployed to generate a frameshift mutation in exon 4 of zebrafish abcb4 ...
July 27, 2023: Research Square
https://read.qxmd.com/read/37520499/progressive-familial-intrahepatic-cholestasis-a-descriptive-study-in-a-tertiary-care-center
#33
JOURNAL ARTICLE
Fahad I Alsohaibani, Musthafa C Peedikayil, Abdulaziz F Alfadley, Mohamed K Aboueissa, Faisal A Abaalkhail, Saleh A Alqahtani
BACKGROUND: Progressive familial intrahepatic cholestasis (PFIC) is a rare genetic disorder that results from defective mechanisms of bile secretion. We aim to describe different types of PFIC and their clinical features, treatment modalities, and outcomes in Saudi Arabia. Patients and Methods . This is a retrospective study of all patients diagnosed with PFIC at King Faisal Specialist Hospital and Research Center in Riyadh from January 1, 2002, to December 31, 2021. All relevant information was collected from patient charts and transferred into the REDcap® database for statistical analysis...
2023: International Journal of Hepatology
https://read.qxmd.com/read/37511794/influence-of-the-bile-acid-transporter-genes-abcb4-abcb8-and-abcb11-and-the-farnesoid-x-receptor-on-the-response-to-ursodeoxycholic-acid-in-patients-with-nonalcoholic-steatohepatitis
#34
JOURNAL ARTICLE
Henriette Kreimeyer, Katharina Vogt, Tobias Götze, Jan Best, Oliver Götze, Jochen Weigt, Alisan Kahraman, Mustafa Özçürümez, Julia Kälsch, Wing-Kin Syn, Svenja Sydor, Ali Canbay, Paul Manka
The prevalence of NAFLD and NASH is increasing worldwide, and there is no approved medical treatment until now. Evidence has emerged that interfering with bile acid metabolism may lead to improvement in NASH. In this study, 28 patients with elevated cholestatic liver function tests (especially GGT) were screened for bile acid gene polymorphisms and treated with UDCA. All patients had a bile acid gene polymorphism in ABCB4 or ABCB11 . Treatment with UDCA for 12 months significantly reduced GGT in all patients and ALT in homozygous patients...
July 24, 2023: Journal of Personalized Medicine
https://read.qxmd.com/read/37488782/analysis-of-various-atp-binding-cassette-transporters-revealed-quantification-of-abcb4-as-a-potential-diagnostic-tool-in-primary-sclerosing-cholangitis-psc
#35
JOURNAL ARTICLE
Cornelia Thoeni, Catia T Perciani, Diana Nakib, Damra Camat, Ian D McGilvray, Sonya A MacParland, Sandra Fischer
AIMS: ATP-binding cassette transporters are important proteins in regulating bile constituent transport between hepatocytes and the bile canalicular system. Dysfunctional transporters lead to accumulation of toxic bile components within hepatocytes or the biliary system, known as cholestasis, resulting in liver damage. It has been previously reported that two particular ATP-binding cassette transporters, ABCB4 and ABCB11, have altered expression in patients with primary sclerosing cholangitis (PSC)...
July 24, 2023: Histopathology
https://read.qxmd.com/read/37488596/a-female-of-progressive-familial-intrahepatic-cholestasis-type-3-caused-by-heterozygous-mutations-of-abcb4-gene-and-her-cirrhosis-improved-after-treatment-of-ursodeoxycholic-acid-a-case-report
#36
JOURNAL ARTICLE
Fei Qiao, Feng Ren, Weiting Lu, Haoran Yang, Guiling Mo, Shuangshuang Wang, Lina Liu, Xiangtao Xu
BACKGROUND: Progressive familial intrahepatic cholestasis (PFIC) is a group of rapidly progressive autosomal recessive disorders characterized by intrahepatic cholestasis. PFIC-3 is caused by mutations in the ATP-binding cassette subfamily B member 4 gene (ABCB4), which encodes multidrug resistance protein 3 (MDR3/ABCB4). Patients are usually in infancy or childhood, but cirrhosis and portal hypertension may be the first manifestation in older children or young adults. CASE PRESENTATION: A 25-year-old young woman with recurrent abnormal hepatic function was mainly characterized by increased gamma glutamyl transpeptidase (GGT) and bile acid with cryptogenic cirrhosis...
July 25, 2023: BMC Medical Genomics
https://read.qxmd.com/read/37471416/exome-sequencing-reveals-ift172-variants-in-patients-with-non-syndromic-cholestatic-liver-disease
#37
JOURNAL ARTICLE
Magdaléna Neřoldová, Elżbieta Ciara, Janka Slatinská, Soňa Fraňková, Petra Lišková, Radana Kotalová, Janka Globinovská, Markéta Šafaříková, Lucie Pfeiferová, Hana Zůnová, Lenka Mrázová, Viktor Stránecký, Alena Vrbacká, Ondřej Fabián, Eva Sticová, Daniela Skanderová, Jan Šperl, Marta Kalousová, Tomáš Zima, Milan Macek, Joanna Pawlowska, A S Knisely, Stanislav Kmoch, Milan Jirsa
BACKGROUND AND AIM: Gene defects contribute to the aetiology of intrahepatic cholestasis. We aimed to explore the outcome of whole-exome sequencing (WES) in a cohort of 51 patients with this diagnosis. PATIENTS AND METHODS: Both paediatric (n = 33) and adult (n = 18) patients with cholestatic liver disease of unknown aetiology were eligible. WES was used for reassessment of 34 patients (23 children) without diagnostic genotypes in ABCB11, ATP8B1, ABCB4 or JAG1 demonstrable by previous Sanger sequencing, and for primary assessment of additional 17 patients (10 children)...
2023: PloS One
https://read.qxmd.com/read/37425689/abcg2a-is-the-functional-homolog-of-human-abcg2-expressed-at-the-zebrafish-blood-brain-barrier
#38
Joanna R Thomas, William J E Frye, Robert W Robey, Andrew C Warner, Donna Butcher, Jennifer L Matta, Tamara C Morgan, Elijah F Edmondson, Michael M Gottesman
A principal protective component of the mammalian blood-brain barrier (BBB) is the high expression of the multidrug efflux transporters P-glycoprotein (P-gp, encoded by ABCB1 ) and ABCG2 (encoded by ABCG2 ) on the luminal surface of endothelial cells. The zebrafish P-gp homolog Abcb4 is expressed at the BBB and phenocopies P-gp. Comparatively little is known about the four zebrafish homologs of the human ABCG2 gene: abcg2a, abcg2b, abcg2c , and abcg2d . Here we report the functional characterization and brain tissue distribution of zebrafish ABCG2 homologs...
May 18, 2023: bioRxiv
https://read.qxmd.com/read/37414142/maternal-hyperglycemia-induces-alterations-in-hepatic-amino-acid-glucose-and-lipid-metabolism-of-neonatal-offspring-multi-omics-insights-from-a-diabetic-pig-model
#39
JOURNAL ARTICLE
Bachuki Shashikadze, Libera Valla, Salvo Danilo Lombardo, Cornelia Prehn, Mark Haid, Fabien Riols, Jan Bernd Stöckl, Radwa Elkhateib, Simone Renner, Birgit Rathkolb, Jörg Menche, Martin Hrabĕ de Angelis, Eckhard Wolf, Elisabeth Kemter, Thomas Fröhlich
OBJECTIVE: To gain mechanistic insights into adverse effects of maternal hyperglycemia on the liver of neonates, we performed a multi-omics analysis of liver tissue from piglets developed in genetically diabetic (mutant INS gene induced diabetes of youth; MIDY) or wild-type (WT) pigs. METHODS: Proteome, metabolome and lipidome profiles of liver and clinical parameters of serum samples from 3-day-old WT piglets (n=9) born to MIDY mothers (PHG) were compared with those of WT piglets (n=10) born to normoglycemic mothers (PNG)...
July 4, 2023: Molecular Metabolism
https://read.qxmd.com/read/37407483/slc25a40-facilitates-anticancer-drug-resistance-in-human-leukemia-k562-cells
#40
JOURNAL ARTICLE
Nodoka Kudo, Rikuma Kouno, Yoshihiko Shibayama
The chronic myelogenous leukemia cell line, K562/ADM is derived from the K562 cell line, which is resistant to doxorubicin (alias, adriamycin: ADM). P-glycoprotein levels are significantly higher in K562/ADM cells than in K562 cells. The overexpression of p-glycoprotein has been shown to cause drug resistance. Therefore, the present study investigated a novel mechanism underlying the drug resistance of K562/ADM cells. A gene ontology analysis demonstrated that the expression of solute carrier (SLC)-mediated transmembrane transport genes was significantly higher in K562/ADM cells than in K562 cells...
September 1, 2023: Biological & Pharmaceutical Bulletin
keyword
keyword
44922
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.